Price Alert

AnaptysBio Inc. (ANAB)

NASDAQ: ANAB · Real-Time Price · USD

32.08

0.25 (0.79%)

At close: Oct 09, 2025, 10:57 AM

0.79% (1D)

Bid	22.98
Market Cap	898.22M
Revenue (ttm)	123.16M
Net Income (ttm)	-132.59M
EPS (ttm)	-4.39
PE Ratio (ttm)	-7.31
Forward PE	-6.13
Analyst	Buy
Dividends	n/a

Ask	40.39
Volume	94,425
Avg. Volume (20D)	556,359
Open	31.95
Previous Close	31.83
Day's Range	31.23 - 32.29
52-Week Range	12.21 - 36.54
Beta	-0.17
Ex-Dividend Date	n/a

About ANAB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANAB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

AnaptysBio Inc. is scheduled to release its earnings on Nov 4, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+31.59%

AnaptysBio shares are trading higher after the com... Unlock content with Pro Subscription

4 months ago

+7.59%

AnaptysBio shares are trading higher after the company announced Rosnilimab data from its six-month Phase 2b trial for rheumatoid arthritis (RA).

News

1 week ago · benzinga.com

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.

1 week ago · seekingalpha.com

AnaptysBio, Inc. - Special Call

AnaptysBio, Inc. - Special Call Company Participants Daniel Faga - President, CEO & Director Dennis Mulroy - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Res...

2 months ago · fool.com

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

2 months ago · zacks.com

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.71 per share a year ago.